MTOR and tuberous sclerosis: The meta-analysis demonstrated a significantly increased response rate in pediatric patients with TSC treated with mTOR inhibitor therapy compared with those treated with non-mTOR inhibitor therapy (odds ratio, 24.71; 95% CI, 7.46–81.72; P<0.001; Fig. 2).